<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00233818</url>
  </required_header>
  <id_info>
    <org_study_id>EC99-07</org_study_id>
    <nct_id>NCT00233818</nct_id>
  </id_info>
  <brief_title>FIM-NL - First-in-Man Study (Netherlands Part) With Sirolimus Coated Modified BX Velocity Stent</brief_title>
  <official_title>An Evaluation of Sirolimus-Coated Modified BX VELOCITY Balloon-Expandable Stents for the Treatment of Patients With de Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the performance and safety of a formulation of the
      antiproliferative agent, sirolimus coated on modified Bx VELOCITY Balloon-Expandable Stent
      mounted on the Raptor Over The Wire (OTW) Stent Delivery System (SDS) in patients with de
      novo coronary artery lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, non-randomized study. Patients who meet the eligibility criteria
      will be treated with the sirolimus coated modified Bx VELOCITY Balloon-Expandable Stent
      mounted on the Raptor OTW SDS. Patients will be followed for five years post-procedure, with
      all patients having a repeat angiography at 6 months, 18 months, and 48 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of in-stent percent diameter stenosis (%DS) measured by quantitative coronary angiography.</measure>
    <time_frame>post procedure and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of lesion morphology by intravascular ultrasound (IVUS).</measure>
    <time_frame>post procedure and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure (TVF).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus-coated Bx VELOCITY Stent</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society
             Classification (CCS) or a positive ischemia study;

          2. Single de novo lesion requiring treatment in a major native coronary artery;

          3. Target lesion is &lt;=18mm in length (visual estimate);

          4. Target lesion is &gt;=3.0mm and &lt;=3.5mm in diameter (visual estimate);

          5. Target lesion stenosis is &gt;50% and &lt;100% (visual estimate);

        Exclusion Criteria:

          1. A Q-wave or non-Q-wave myocardial infarction within the preceding 72 hours unless the
             CK and CK-MB enzymes are back to normal;

          2. Unprotected left main coronary disease with &gt;=50% stenosis;

          3. Have an ostial target lesion;

          4. Angiographic evidence of thrombus within target lesion;

          5. Calcified lesions which cannot be successfully predilated;

          6. Ejection fraction &lt;=30%;

          7. Target lesion involves bifurcation (either stenosis of both main vessel and major
             branch or stenosis of just major branch);

          8. Totally occluded vessel;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick W Serruys, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Centrum Thoraxcentrum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erasmus Centrum Thoraxcentrum</name>
      <address>
        <city>Rotterdam</city>
        <zip>NL- 3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Rensing BJ, Vos J, Smits PC, Foley DP, van den Brand MJ, van der Giessen WJ, de Feijter PJ, Serruys PW. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J. 2001 Nov;22(22):2125-30.</citation>
    <PMID>11686669</PMID>
  </results_reference>
  <results_reference>
    <citation>Degertekin M, Serruys PW, Foley DP, Tanabe K, Regar E, Vos J, Smits PC, van der Giessen WJ, van den Brand M, de Feyter P, Popma JJ. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation. 2002 Sep 24;106(13):1610-3.</citation>
    <PMID>12270850</PMID>
  </results_reference>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2005</study_first_posted>
  <last_update_submitted>October 11, 2007</last_update_submitted>
  <last_update_submitted_qc>October 11, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

